The financial toxicity of oncology treatments

Blood cancers

15 Oct 2015

In this Lancet podcast Scott Huntington from Abramson Cancer Center at the University of Pennsylvania talks about how financial toxicity is increasingly recognised as adversely affecting the quality of life and medication adherence in patients with cancer in the USA.

Patients with multiple myeloma might be particularly vulnerable because of high use of novel treatments and extended treatment duration.

Already a member?

Login to keep reading.

Email me a login link